 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...1415161718192021222324...3233» |
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
I am super pumped as you can just write an Rx and they T can be castrate so rapidly. Look at it compared to lupron: (Twitter) - Dec 18, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
I think adoption will depend on urology patterns - if referring recommends Lupron and then referred, will be hard to change immediately (Twitter) - Dec 18, 2020
- ||||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Relumina (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Clinical: Relugolix is approved as an oral androgen deprivation therapy for prostate cancers! We had pts on trial @DukeGUCancer led by @Daniel_J_George @M_FerrandinoMD 👉🏼 short acting, fast testosterone recovery 👉🏼 lower cardiovascular events vs Lupron 👉🏼 good for intermittent ADT (Twitter) - Dec 18, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical, Monotherapy: Given continued lupron shortage and COVID, I would imagine fairly rapid adoption, especially to get started on ADT. Some will then convert after to injections Wont be for all patients. As always there will be late adopters who still use bicalutamide monotherapy😂 (Twitter) - Dec 18, 2020
- |||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical, Adverse events: Also there’s no vaccine or cure for endometriosis. The only thing that is done that helps is surgery. The “medicine” they give: depo shot, Lupron, etc. have horrible side effects that make it worse. Something that is under diagnosed and disables women. No help for us. (Twitter) - Dec 15, 2020
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
.@FDA_Drug_Info thanks for letting #Lupron literally ruining my life, degenerated bones, bells palsy, skyrocketed TSH, now signs of Dementia (Twitter) - Dec 13, 2020
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Bring the Lupron back!! No more shortage!! (Twitter) - Dec 13, 2020
- ||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion, Trial completion date, Trial primary completion date: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis (clinicaltrials.gov) - Dec 11, 2020
P3, N=335, Completed, Sponsor: ASKA Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Sep 2020 | Trial primary completion date: Mar 2021 --> Jun 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: Anything better than an AI plus Lupron yet for premenopausal women? 🤞🙏😩 (Twitter) - Dec 10, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Any thoughts on the impact of molecular subtype for this scenario? Saw a recent report showing high AR-A is associated with PSMA expression. Was faced with a situation identical to the one you posted except the solitary met was in the C-spine. Opted to put him on Lupron/ apa. (Twitter) - Dec 4, 2020
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: BASH-PC: Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (clinicaltrials.gov) - Dec 3, 2020
P2, N=20, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Sep 2020 | Trial primary completion date: Mar 2021 --> Jun 2020 Not yet recruiting --> Recruiting
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Relumina (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Tune in now to SUO 2020 to hear from Neal Shore why GnRH antagonists should be the SOC. Discusses the now numerous studies demonstrating lower cardiac events in antagonists compared to agonists (e.g. lupron). Discusses the advantages of Relugolix (and Degaralix) over lupron. (Twitter) - Dec 3, 2020
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Trial primary completion date: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Dec 3, 2020
P3, N=45, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2021 --> May 2021
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Agree. NOT unique to lung cancer. I don't follow prostate cancer as well as I used to, but it's also historically often been an opportunity to test new drug vs. just ongoing Lupron despite rising PSA, no crossover. Talk about keeping your finger on the scale... (Twitter) - Nov 21, 2020
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda
A collective, enormous fuck you for pushing Lupron as an effective treatment, you pieces of shit - sincerely, every endo sufferer on earth (Twitter) - Nov 17, 2020
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
how about updated support relief for victims on #Lupron ruining their lives, no comment? #prostatecancer I'll wait.. (Twitter) - Nov 16, 2020
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Nov 13, 2020
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2021 --> May 2021 Trial primary completion date: Sep 2020 --> May 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Trial initiation date, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Nov 12, 2020
P3, N=1002, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2020 --> May 2021 Initiation date: Sep 2020 --> Jan 2021
- Lupron Depot (leuprorelin depot) / AbbVie, Takeda
[VIRTUAL] Mood disorders during reproductive transitions: circuit and cellular substrates of risk () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_174;
Finally, preliminary network analysis of E2-exposed LCLs implicates DEGs involved in intracellular calcium regulation (NUCB1, GCC2, TRPM7; P<.01) in PMDD. These data demonstrate that the differential behavioral sensitivity in women with PMDD is paralleled by rCBF (in vivo) and cellular transcription (in vitro) responses to ovarian steroids.
- |||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: There are some apparent effective adjuvant treatments lupron abi taxol etc combo ? Maybe not well tested here but if the probability of metastasis is high enough I would to that plus local rx (Twitter) - Oct 29, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Given my choice xrt Lupron abi maybe image psma for oligo (Twitter) - Oct 28, 2020
- Xtandi (enzalutamide) / Pfizer, Astellas, Lupron Depot (leuprorelin depot) / AbbVie, Takeda
[VIRTUAL] Macrophages regulate androgen receptor activation in prostate cancer () - Oct 25, 2020 - Abstract #PCF2020PCF_27;
Our findings show that depleting macrophage using a neutralizing antibody against colony-stimulating factor (CSF)-1 in combination with ADT (Lupron) significantly extended survival of mice-bearing orthotoptic prostate tumors, compared with each agent alone...These findings were recapitulated in vitro, with the co-culture of macrophages and prostate cancer cells enhancing AR nuclear translocation, increasing cancer cell proliferation in androgen-deprived conditions, and reducing sensitivity to the AR antagonist, enzalutamide...In conclusion, macrophages regulate androgen levels in prostate tumors and contribute to resistance to ADT. Funding Acknowledgments: Prostate Cancer Foundation young investigator and Department of Defense award (CDMRP-PC181013) to Kosj Yamoah, MD, PhD.
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: I have started to move towards just starting ADT when they start Xrt especially when they are traveling from far away. They get a sim and then lupron when we start. Decreases trips for patients #financialtoxicity (Twitter) - Oct 24, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical, HEOR: I'd still love to see a cost-benefit analysis of an on-patent oral GnRH vs Deg-->Lupron strategy. Not convinced it's the "right" thing from a cost containment/systems standpoint, especially if pts have OOP expenses (e.g. Abi). (Twitter) - Oct 24, 2020
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda
.@FDA_Drug_Info update, after 5-90 injections of #Lupron TSH now at 104.3. Under control prior. @HypothyroidMom (Twitter) - Oct 20, 2020
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Good because lupron was made for prostate cancer. (Twitter) - Oct 19, 2020
- | Erleada (apalutamide) / J&J
Trial completion, Trial completion date, Trial primary completion date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Oct 19, 2020
P2, N=54, Completed, Sponsor: Case Comprehensive Cancer Center
Funding Acknowledgments: Prostate Cancer Foundation young investigator and Department of Defense award (CDMRP-PC181013) to Kosj Yamoah, MD, PhD. Recruiting --> Completed | Trial completion date: Dec 2020 --> May 2020 | Trial primary completion date: Dec 2020 --> May 2020
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
hope it's safe. #Lupron is lethal and the @US_FDA knows this. Battling prostate cancer on Lupron has ruined my life (Twitter) - Oct 16, 2020
- || leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov) - Oct 12, 2020
P1/2, N=100, Recruiting, Sponsor: University of Michigan Rogel Cancer Center
Recruiting --> Completed | Trial completion date: Dec 2020 --> May 2020 | Trial primary completion date: Dec 2020 --> May 2020 Trial completion date: Feb 2027 --> Jun 2027 | Initiation date: Aug 2020 --> Dec 2020 | Trial primary completion date: Aug 2026 --> Dec 2026
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion: Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) - Oct 12, 2020
P2, N=7, Completed, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Feb 2027 --> Jun 2027 | Initiation date: Aug 2020 --> Dec 2020 | Trial primary completion date: Aug 2026 --> Dec 2026 Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 6, 2020
P2, N=92, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Preclinical, Journal: Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres. (Pubmed Central) - Oct 3, 2020
In conclusion, these results indicate the sensitivity of peptide release, and hence, the safety and efficacy of highly potent peptide microspheres, to minor manufacturing changes. Accordingly, development of IVIVCs for such complex drug products is highly desirable.
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 1, 2020
P1, N=26, Completed, Sponsor: Rutgers, The State University of New Jersey
Accordingly, development of IVIVCs for such complex drug products is highly desirable. Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Jan 2020 | Trial primary completion date: Aug 2021 --> Jan 2020
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open: CARABELA: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (clinicaltrials.gov) - Sep 29, 2020
P2, N=200, Recruiting, Sponsor: Spanish Breast Cancer Research Group
Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Jan 2020 | Trial primary completion date: Aug 2021 --> Jan 2020 Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Sep 29, 2020
P2, N=375, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) - Sep 28, 2020
P2, N=11, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Preclinical, Journal: In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release. (Pubmed Central) - Sep 27, 2020
Moreover, it was observed that IVIVCs developed using formulations with less variation in burst release had better predictability and vice-versa. Thus, the present research has provided a comprehensive understanding of the impact of the burst release phase on the development, complexity, and predictability of IVIVCs for complex parenteral microspheres containing a variety of therapeutic molecules.
- | leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) - Sep 24, 2020
P=N/A, N=72, Suspended, Sponsor: University of Colorado, Denver
Thus, the present research has provided a comprehensive understanding of the impact of the burst release phase on the development, complexity, and predictability of IVIVCs for complex parenteral microspheres containing a variety of therapeutic molecules. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- |||||| Erleada (apalutamide) / J&J
Enrollment open: CARLHA-2: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (clinicaltrials.gov) - Sep 23, 2020
P3, N=490, Recruiting, Sponsor: UNICANCER
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Suspended --> Recruiting
- Lupron Depot (leuprorelin depot) / AbbVie, Takeda
[VIRTUAL] Outcomes of Incarcerated Federal Prisoners Treated with Radiation Therapy for Newly Diagnosed Prostate Cancer (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1104;
Radiation therapy is delivered via IMRT technique with morbidity and outcomes appearing equivalent to those published in the literature. With no prostate cancer screening in place ,higher volume and higher Gleason tumors are encountered.
- || Orilissa (elagolix) / AbbVie
Enrollment open: Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis (clinicaltrials.gov) - Sep 9, 2020
P1, N=30, Recruiting, Sponsor: Colorado Center for Reproductive Medicine
With no prostate cancer screening in place ,higher volume and higher Gleason tumors are encountered. Not yet recruiting --> Recruiting
- |||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical: 3. It appears the patient is unblinded - could there be a risk of bias in the composite primary outcome? Could a patient on Lupron feel b/c he is in the "high risk" arm that his chest pain may be a MI but similar symptoms in one in the "low risk" arm not prompt presentation? (Twitter) - Aug 30, 2020
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Firmagon (degarelix) / Astellas, Ferring
Cons are: 1. Only approved agent is degarelix which has a way higher injection site reactions than lupron. 35% have injection site reactions and a fair number have pain, swelling, and even a few percent grade 3 reactions on their label. 2. Degarelix requires monthly shots 😞 (Twitter) - Aug 29, 2020
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P3 trial: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Aug 13, 2020
P3, N=2478, Not yet recruiting, Sponsor: NRG Oncology
- | Livial (tibolone) / Organon
Trial completion date, Trial primary completion date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Aug 12, 2020
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Jan 2021
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Aug 11, 2020
P2, N=257, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Jan 2021 Trial primary completion date: Mar 2020 --> Jul 2020
- | Trial completion, Metastases: LEO: Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2020
P2, N=137, Completed, Sponsor: Asan Medical Center
Trial primary completion date: Mar 2020 --> Jul 2020 Recruiting --> Completed
- | Erleada (apalutamide) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (clinicaltrials.gov) - Aug 8, 2020
P2, N=42, Active, not recruiting, Sponsor: Tian Zhang, MD
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Feb 2023 | Trial primary completion date: Mar 2024 --> Feb 2023
- ||| leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Enrollment open: ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov) - Aug 7, 2020
P1/2, N=100, Recruiting, Sponsor: University of Michigan Rogel Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Feb 2023 | Trial primary completion date: Mar 2024 --> Feb 2023 Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment open, Trial initiation date: Skeletal Health and Bone Marrow Composition Among Youth (clinicaltrials.gov) - Aug 7, 2020
P=N/A, N=80, Recruiting, Sponsor: Boston Children
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Aug 2020